Nautilus Biotechnology (NAUT) Cash & Current Investments (2020 - 2026)

Nautilus Biotechnology (NAUT) has 7 years of Cash & Current Investments data on file, last reported at $95.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 30.94% year-over-year to $95.9 million; the trailing twelve-month figure through Mar 2026 stood at $95.9 million (down 30.94% YoY), and the FY2025 full-year result was $103.4 million, down 20.39% from the prior year.
• Cash & Current Investments retreated to $95.9 million in Q1 2026, from $103.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $324.1 million in Q1 2022 to a low of $95.9 million in Q1 2026.
• A 5-year average of $175.9 million and a median of $167.3 million in 2023 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments soared 47423.79% in 2022 and sank 48.37% in 2023, its largest moves.
• Tracing NAUT's Cash & Current Investments over 5 years: stood at $184.5 million in 2022, then declined by 5.99% to $173.4 million in 2023, then retreated by 25.1% to $129.9 million in 2024, then retreated by 20.39% to $103.4 million in 2025, then fell by 7.29% to $95.9 million in 2026.
• Business Quant data shows NAUT's Cash & Current Investments at $95.9 million in Q1 2026, $103.4 million in Q4 2025, and $131.4 million in Q3 2025.